Why Sonoma Pharmaceuticals (SNOA) Stock Is Moving
Sonoma Pharmaceuticals Inc SNOA shares are trading lower by 11.9% to $0.19 Wednesday morning after the company announced a 1-for-20 reverse stock split.
The stock will trade on a split-adjusted basis starting August 30, 2024. This move aims to meet Nasdaq’s $1.00 minimum bid price requirement. As a result, every 20 shares of Sonoma’s common stock will be consolidated into one share, reducing the total outstanding shares from 20 million to 1 million.
No fractional shares will be issued; instead, shareholders will receive cash for any fractions. The authorized shares will also increase from 24 million to 50 million.
Should I Sell My SNOA Stock?
Whether to sell or hold a stock largely depends on an investor’s strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Sonoma Pharmaceuticals have lost 75.9% year to date. This compares to the average annual return of -66.61%, meaning the stock has underperformed its historical averages. Investors can compare a stock’s movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
SNOA has a 52-week high of $1.02 and a 52-week low of $0.12.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
IMPERIAL EQUITIES INC. GRANTS STOCK OPTIONS
EDMONTON, AB, Aug. 27, 2024 /CNW/ – Imperial Equities Inc. IEI, through its Board of Directors today announced that effective August 26th, 2024, it has approved a grant of stock options to a Director and Officer of Imperial Equities Inc.
The Director can purchase an aggregate of 200,000 common shares at an exercise price of $4.00 per common share pursuant to its stock option plan. The stock options expire five years from the date of grant, and vest immediately.
About Imperial Equities Inc:
Based in Edmonton, Alberta, Imperial Equities Inc. is a publicly traded company anchored by industrial, agricultural, and commercial real estate properties in its targeted markets throughout Western Canada.
Additional information is available at: www.imperialequities.com. Imperial’s common shares are listed on the TSX Venture Exchange under symbol IEI.
Neither TSX Venture nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
SOURCE Imperial Equities Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2024/27/c3553.html
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SenesTech Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on July 25, 2024
PHOENIX, July 23, 2024 /PRNewswire/ — SenesTech, Inc. SNES “, SenesTech”, or the “, Company”, ))) (www.senestech.com) the leader in fertility control to manage animal pest populations, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:01 p.m, Eastern Time, on July 24, 2024. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “SNES” and will begin trading on a split-adjusted basis when the market opens on July 25, 2024.
At the annual meeting of stockholders held on July 11, 2024, the Company’s stockholders granted the Company’s Board of Directors the discretion to effect a reverse stock split of the Company’s common stock through an amendment to its Amended and Restated Certificate of Incorporation, as amended, at a ratio of not less than 1-for-2 and not more than 1-for-20, with such ratio to be determined by the Company’s Board of Directors.
At the effective time of the reverse stock split, every 10 shares of the Company’s issued common stock will be converted automatically into one issued share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of the Company’s common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split will either be (i) rounded up to the nearest whole share of common stock, if such shares of common stock are held directly; or (ii) rounded down to the nearest whole share of common stock, if such shares are subject to an award granted under the Company’s 2018 Equity Incentive Plan, in order to comply with the requirements of Sections 409A and 424 of the Internal Revenue Code of 1986. The reverse stock split will reduce the number of issued shares of the Company’s common stock from 5,144,632 shares to approximately 514,464 shares. Proportional adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise or conversion of SenesTech’s equity awards and warrants, as well as the applicable exercise price. Stockholders whose shares are held in brokerage accounts should direct any questions concerning the reverse stock split to their broker. All stockholders of record may direct questions to the Company’s transfer agent, Transfer Online, Inc., at (503) 227-2950.
About SenesTech
We are committed to improving the health of the world by humanely managing animal pest populations through fertility control. We are experts in fertility control to manage animal pest populations. We invented ContraPest®, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve™, an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses, and happy households – with a product designed to be humane, effective and sustainable.
For more information visit https://senestech.com/.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, the expected timing of the reverse stock split and number of shares outstanding after the reverse stock split. Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as “believe,” “may,” “future,” “plan,” “will,” “should,” “expect,” “anticipate,” “eventually,” “project,” “estimate,” “continuing,” “intend” and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products; market acceptance of our products; our financial performance, including our ability to fund operations; our ability to regain and maintain compliance with Nasdaq’s continued listing requirements; and regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACT:
Investors: Robert Blum, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com
Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143
View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-announces-reverse-stock-split-302204232.html
SOURCE SenesTech, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Why Evoke Pharma (EVOK) Stock Is Volatile
Evoke Pharma Inc EVOK shares ended Tuesday down 16.40% to 42 cents after the company announced a 1-for-12 reverse stock split of its common stock, set to take effect at 12:01 a.m. ET on August 1, 2024. After-hours trading has it up 12.44% at 47 cents.
The reverse stock split means that every 12 shares of the company’s existing common stock will be consolidated into one share. The stock will trade on a split-adjusted basis on NASDAQ under the same symbol, EVOK, starting Aug. 1.
This reverse split, approved by shareholders at the 2024 annual meeting, will not change the par value or the authorized number of shares. Fractional shares will not be issued; instead, shareholders will receive a cash payment for any fractional shares.
Should I Buy, Hold or Sell My EVOK Stock?
When deciding to buy, hold or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Evoke Pharma have decreased by 75.13% in the past year. An investor who bought shares of Evoke Pharma at the beginning of the year would take a loss of $0.64 per share if they sold it today. The stock has fallen 16.7% over the past month, meaning an investor who bought shares on Jun. 1 would see a capital loss of $0.11.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Evoke Pharma stock currently has an RSI of 28.29, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
EVOK has a 52-week high of $1.67 and a 52-week low of 36 cents.
Read Next:
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ginkgo Bioworks to Hold Special Meeting of Shareholders
Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET
BOSTON, Aug. 2, 2024 /PRNewswire/ — Ginkgo Bioworks Holdings, Inc. DNA “, Ginkgo”, ))), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a range of not less than one-for-twenty (1:20) and not more than one-for-forty (1:40), with the final ratio to be determined by the Board of Directors. Shareholders will also vote to approve Ginkgo’s Amended and Restated Certificate of Incorporation, which has been updated to permit officer exculpation and remove provisions related to our merger with Soaring Eagle Acquisition Corp. and our domestication process, which are no longer relevant to our business.
Additional information regarding the special meeting, including how to vote, are available via proxy materials filed by Ginkgo with the U.S. Securities and Exchange Commission (the “SEC”), and can be found here.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
MEDIA CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-to-hold-special-meeting-of-shareholders-302210173.html
SOURCE Ginkgo Bioworks
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Siyata Announces Reverse Stock Split
Reverse Stock-Split to be effective on August 2, 2024
VANCOUVER, BC, July 31, 2024 /PRNewswire/ — Siyata Mobile Inc. SYTA SYTAW))) (“Siyata” or the “Company“), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, today announced that it will effect a 1-for-18 reverse stock split (“Reverse Stock Split”) of its common share, no par value per share (“Common Share”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on Friday, August 2, 2024, and the Company’s Common Share will commence trading on the Nasdaq Capital Market on a post-split basis at the opening of the market on August 2, 2024. The Company’s Common Share will continue to trade on the Nasdaq Capital Market under the Company’s existing trading symbol, “SYTA,” and a new CUSIP number 83013Q 806 has been assigned as a result of the Reverse Stock Split.
The Reverse Stock Split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee the Company will meet the minimum bid price requirement.
The 1-for-18 reverse stock split (the “Ratio”) will automatically combine and convert 18 current shares of the Company’s Common Share into one issued and outstanding new share of Common Share. Each outstanding stock option, pre-funded warrant, share purchase warrant, and other convertible security of the Company convertible into pre-Reverse Stock Split Common Shares that has not been exercised or cancelled prior to the effective date of the implementation of the Reverse Stock Split will be adjusted pursuant to the terms of the instrument or plan governing such security on the same Reverse Stock Split Ratio described above, and each holder of such pre-Reverse Stock Split convertible securities will become entitled to receive post-Reverse Stock Split Common Shares pursuant to such adjusted terms. The Reverse Stock Split will not change the par value of the Common Share nor the authorized number of shares of Common Share, preferred stock or any series of preferred stock.
No fractional shares will be issued in connection with the Reverse Stock Split. All fractional shares will be rounded up to the next higher whole number.
The Company’s transfer agent, Computershare, will serve as exchange for the Reverse Stock Split. Registered shareholders holding pre-split shares of the Company’s Common Share electronically in book-entry form are not required to take any action to receive post-split shares. Shareholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such broker’s particular processes, and will not be required to take any action in connection with the Reverse Stock Split. Holders of stock certificates will need to send their old physical certificates with a letter of transmittal to receive their new post-Reverse Stock Split certificate.
About Siyata Mobile
Siyata Mobile Inc. is a B2B global vendor of next generation Push-To-Talk over Cellular devices, cellular booster systems, and video monitoring solutions. Its portfolio of in-vehicle and rugged devices enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives.
Its portfolio of enterprise grade and consumer cellular booster systems enables first responders and enterprise workers to amplify cellular signals in remote areas, inside structural buildings where signals are weak and within vehicles for the maximum cellular signal strength possible.
For its video monitoring system, Siyata integrates software that we license with off-the-shelf hardware providing our customers with an integrated advanced camera system for management and visual monitoring of their fleet vehicles.
Siyata’s Common Shares trade on the Nasdaq under the symbol “SYTA” and its previously issued warrants trade on the Nasdaq under the symbol “SYTAW.”
Visit siyatamobile.com and unidencellular.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Siyata’s filings with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites and social media have been provided as a convenience, and the information contained on such websites or social media is not incorporated by reference into this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/siyata-announces-reverse-stock-split-302210778.html
SOURCE Siyata Mobile Inc.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Neque Porro Quisquam Est
Aliquam congue fermentum nisl. Mauris accumsan nulla vel diam. Sed in lacus ut enim adipiscing aliquet. Nulla venenatis. In pede mi, aliquet sit amet, euismod in, auctor ut, ligula. Aliquam dapibus tincidunt metus. Praesent justo dolor, lobortis quis, lobortis dignissim, pulvinar ac, lorem.
Sed Ut Perspiciatis Unde
Aliquam congue fermentum nisl. Mauris accumsan nulla vel diam. Sed in lacus ut enim adipiscing aliquet. Nulla venenatis. In pede mi, aliquet sit amet, euismod in, auctor ut, ligula. Aliquam dapibus tincidunt metus. Praesent justo dolor, lobortis quis, lobortis dignissim, pulvinar ac, lorem.
Aliquam Dapibus Tincidunt
Aliquam congue fermentum nisl. Mauris accumsan nulla vel diam. Sed in lacus ut enim adipiscing aliquet. Nulla venenatis. In pede mi, aliquet sit amet, euismod in, auctor ut, ligula. Aliquam dapibus tincidunt metus. Praesent justo dolor, lobortis quis, lobortis dignissim, pulvinar ac, lorem.
Fusce Euismod Consequat
Aliquam congue fermentum nisl. Mauris accumsan nulla vel diam. Sed in lacus ut enim adipiscing aliquet. Nulla venenatis. In pede mi, aliquet sit amet, euismod in, auctor ut, ligula. Aliquam dapibus tincidunt metus. Praesent justo dolor, lobortis quis, lobortis dignissim, pulvinar ac, lorem.